本文翻译正在准备中。在此之前，我们暂时显示英文原文。
商业 · 2026/11/101 分钟阅读
Pharma firms’ focus on weight-loss drugs could put insulin supply at risk, experts warn
本地自动翻译 · 来源原始语言
摘要
GLP-1 products such as Ozempic and Mounjaro spread but many in poorer countries struggle to get basic diabetes treatment The gold rush into GLP-1 weight-loss drugs risks diverting pharmaceutical firms’ attention…
来源原始语言: The Guardian Business — International business news打开原始公告 →